JadiCells, the investigational stem cell therapy, restored lung function and increased the number of cells which have a role in lung repair in mice model with inflammation-induced lung injury. The preclinical findings from the ongoing investigation by Therapeutic Solutions International (TSOI) with these mesenchymal stem cells (MSC) derived from cell lining of umbilical cord, further support its potential to both prevent excessive inflammation and lung injury and also repair established lung tissue damage as seen in chronic lung diseases such as COPD and idiopathic pulmonary fibrosis (IPF). TSOI has already filed a patent covering the therapeutic use of JadiCells and its multiple combinations in COPD. The therapy is currently being tested in clinical trials for treating severe COVID-19 patients and has shown promising results.